Happy!Days!
"It's definitely the correct forum. shareholders/fund managers can't give us upfront and milestone payments only the pharma world can."
There are two groups involved in these deals - the scientists who do the Due Diligence and evaluate the product as that, a product. Then there are the suits, who work out which products interest them in the first place, costings, size of potential market, how much first mover advantage they hold and eventually the deal.
The presentation was not for the second group, so again I would question the impact the presentation was going to have on the market. It is just past midday on the market and only 100,000 shares through after what we all thought could be a major turning point in the Suda story - I think the market clearly does not understand what it was we presented, and if I am perfectly honest - nor do I, and I'm interested.
Clyde
Add to My Watchlist
What is My Watchlist?
